UBS Group’s BioLineRX BLRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $315 | Sell |
101
-428
| -81% | -$1.24K | ﹤0.01% | 9931 |
|
|
2026
Q1 | $1.22K | Sell |
529
-1,422
| -73% | -$3.99K | ﹤0.01% | 9583 |
|
|
2025
Q4 | $5.4K | Sell |
1,951
-4,436
| -69% | -$15.3K | ﹤0.01% | 8687 |
|
|
2025
Q3 | $24.1K | Buy |
+6,387
| New | +$25.6K | ﹤0.01% | 8035 |
|
|
2025
Q2 | – | Sell |
-71
| Closed | -$210 | – | 10271 |
|
|
2025
Q1 | $210 | Sell |
71
-159
| -69% | -$640 | ﹤0.01% | 9884 |
|
|
2024
Q4 | $1.97K | Buy |
230
+205
| +820% | +$3.02K | ﹤0.01% | 9130 |
|
|
2024
Q3 | $527 | Sell |
25
-12
| -32% | -$330 | ﹤0.01% | 8909 |
|
|
2024
Q2 | $844 | Sell |
37
-277
| -88% | -$7.44K | ﹤0.01% | 8759 |
|
|
2024
Q1 | $14.1K | Buy |
314
+306
| +3,825% | +$15.3K | ﹤0.01% | 7080 |
|
|
2023
Q4 | $471 | Sell |
8
-224
| -97% | -$13.9K | ﹤0.01% | 8647 |
|
|
2023
Q3 | $16.9K | Sell |
232
-31
| -12% | -$2.08K | ﹤0.01% | 6892 |
|
|
2023
Q2 | $16.8K | Buy |
+263
| New | +$14.6K | ﹤0.01% | 6950 |
|
|
2023
Q1 | – | Sell |
-96
| Closed | -$2.26K | – | 9626 |
|
|
2022
Q4 | $2.26K | Sell |
96
-224
| -70% | -$6.66K | ﹤0.01% | 9709 |
|
|
2022
Q3 | $12K | Buy |
+320
| New | +$18.3K | ﹤0.01% | 8144 |
|
|
2021
Q3 | – | Sell |
-157
| Closed | -$18K | – | 9546 |
|
|
2021
Q2 | $18K | Sell |
157
-25
| -14% | -$2.94K | ﹤0.01% | 7440 |
|
|
2021
Q1 | $20K | Buy |
182
+31
| +21% | +$3.73K | ﹤0.01% | 7373 |
|
|
2020
Q4 | $15K | Buy |
151
+47
| +45% | +$4.11K | ﹤0.01% | 7153 |
|
|
2020
Q3 | $7K | Buy |
+104
| New | +$7.86K | ﹤0.01% | 7094 |
|
|
2019
Q4 | – | Sell |
-27
| Closed | -$3K | – | 8107 |
|
|
2019
Q3 | $3K | Buy |
+27
| New | +$3.75K | ﹤0.01% | 7620 |
|
|
2019
Q2 | – | Sell |
-20
| Closed | -$5K | – | 7855 |
|
|
2019
Q1 | $5K | Buy |
20
+3
| +18% | +$874 | ﹤0.01% | 7146 |
|
|
2018
Q4 | $4K | Buy |
+17
| New | +$8.18K | ﹤0.01% | 7616 |
|
|
2018
Q3 | – | Sell |
-13
| Closed | -$7K | – | 7979 |
|
|
2018
Q2 | $7K | Buy |
+13
| New | +$6.9K | ﹤0.01% | 7318 |
|
|
2018
Q1 | – | Sell |
-74
| Closed | -$48K | – | 7811 |
|
|
2017
Q4 | $48K | Buy |
74
+71
| +2,367% | +$46.8K | ﹤0.01% | 5864 |
|
|
2017
Q3 | $2K | Buy |
+3
| New | +$1.86K | ﹤0.01% | 7458 |
|
|
2017
Q1 | – | Sell |
-25
| Closed | -$14K | – | 7639 |
|
|
2016
Q4 | $14K | Buy |
25
+12
| +92% | +$7.46K | ﹤0.01% | 6718 |
|
|
2016
Q3 | $9K | Sell |
13
-47
| -78% | -$25K | ﹤0.01% | 6834 |
|
|
2016
Q2 | $29K | Buy |
60
+57
| +1,900% | +$31.9K | ﹤0.01% | 5957 |
|
|
2016
Q1 | $2K | Sell |
3
-11
| -79% | -$6.91K | ﹤0.01% | 7296 |
|
|
2015
Q4 | $11K | Buy |
14
+8
| +133% | +$6.64K | ﹤0.01% | 7213 |
|
|
2015
Q3 | $6K | Buy |
+6
| New | +$6.4K | ﹤0.01% | 7586 |
|
|
2015
Q2 | – | Sell |
-13
| Closed | -$17K | – | 8491 |
|
|
2015
Q1 | $17K | Buy |
+13
| New | +$16K | ﹤0.01% | 7133 |
|
Other funds holding BLRX
BCV
NA
SS
DB
UBS Group's BLRX Position: Q2 2026 in Review
UBS Group reduced its BioLineRX (BLRX) stake by 81% in Q2 2026, selling an estimated $1.24K and leaving 101 shares worth $315. The position accounts for ﹤0.01% of the portfolio, ranked #9931.
UBS Group first reported a position in BLRX in Q1 2015 and has held it in 31 quarters since. The position peaked at $48K in Q4 2017. 9 funds tracked by Wall St. Rank hold BLRX as of Q2 2026.
- UBS Group held 101 shares of BioLineRX worth $315 as of Q2 2026.
- UBS Group sold 428 BioLineRX shares in Q2 2026, an estimated $1.24K.
- BioLineRX made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9931 holding.
- UBS Group first reported a position in BioLineRX in Q1 2015 and has held it in 31 quarters since.
- UBS Group's BioLineRX position peaked at $48K in Q4 2017.
- 9 funds tracked by Wall St. Rank held BioLineRX as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.